This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Novartis Ag, Intellia Therapeutics, Inc.. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- San Diego, CA (US) (2022)
- El Cerrito, CA (US) (2022)
Company Filing History:
3 out of 3,977 
2 out of 20 Years Active: 2022-2026
Title: The Innovative Contributions of Christian Schmedt
Introduction
Christian Schmedt is a notable inventor based in El Cerrito, CA, who has made significant contributions to the field of biotechnology. With a focus on genome editing and therapeutic methods, he has been awarded 3 patents that showcase his innovative spirit and dedication to advancing medical science.
Latest Patents
Schmedt's latest patents include groundbreaking work in the treatment of hemoglobinopathies. His first patent is directed to genome editing systems, reagents, and methods specifically designed for this purpose. The second patent involves novel compositions, methods, and therapeutic uses related to a fusogenic protein known as MINION (microprotein inducer of fusion). These inventions highlight his commitment to developing effective treatments for complex medical conditions.
Career Highlights
Throughout his career, Schmedt has worked with prominent companies in the biotechnology sector, including Novartis AG and Intellia Therapeutics, Inc. His experience in these organizations has allowed him to collaborate with leading experts and contribute to cutting-edge research and development.
Collaborations
Some of Schmedt's notable coworkers include Stephane Corbel and Srihari Cidambi Sampath. Their collaborative efforts have further enriched the innovative projects they have undertaken together.
Conclusion
Christian Schmedt's contributions to biotechnology through his patents and collaborations reflect his dedication to improving healthcare solutions. His work continues to inspire advancements in the treatment of genetic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile